Falcon Point Capital’s Aldeyra Therapeutics ALDX Stock Holding History

Falcon Point Capital’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-25,118	Closed	-$140K	–	110
2019 Q3	$140K	Buy	25,118 +417	+2%	+$2.25K	0.08%	101
2019 Q2	$148K	Buy	24,701 +280	+1%	+$2.11K	0.08%	100
2019 Q1	$221K	Buy	24,421 +580	+2%	+$4.93K	0.12%	94
2018 Q4	$198K	Sell	23,841 -4,931	-17%	-$50.5K	0.12%	93
2018 Q3	$397K	Sell	28,772 -5,197	-15%	-$42.2K	0.09%	81
2018 Q2	$270K	Buy	+33,969	New	+$271K	0.05%	105

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

Falcon Point Capital's ALDX Position: Q4 2019 in Review

Falcon Point Capital sold out of Aldeyra Therapeutics (ALDX) in Q4 2019, closing a stake of 25,118 shares — an estimated $140K sold.

Falcon Point Capital first reported a position in ALDX in Q2 2018 and held it in 6 quarters. The position peaked at $397K in Q3 2018. 77 funds tracked by Wall St. Rank hold ALDX as of Q4 2019.

Falcon Point Capital reported no remaining Aldeyra Therapeutics position as of Q4 2019 after selling out during the quarter.
Falcon Point Capital sold 25,118 Aldeyra Therapeutics shares in Q4 2019, an estimated $140K.
Falcon Point Capital first reported a position in Aldeyra Therapeutics in Q2 2018 and held it in 6 quarters.
Falcon Point Capital's Aldeyra Therapeutics position peaked at $397K in Q3 2018.
77 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2019.

Based on Falcon Point Capital's 13F filing for Q4 2019, filed 23 Jan 2020.